The Latest Updates from ReSPECT Clinical Trials

Last month, several of the world’s leading experts in leptomeningeal metastases (LM) came together at the American Society of Clinical Oncology (ASCO) / Society for Neuro-Oncology (SNO) CNS Metastases Conference to share insights, research, and clinical updates on...

Last week, the leadership teams of Plus Therapeutics and CNSide Diagnostics came together onsite at the SNO/ASCO 2025 CNS Metastases Conference to advance the dialogue on leptomeningeal metastases (LM). LM Symposium The jointly sponsored LM presentation and panel...

The Leptomeningeal Cancer Foundation is hosting an important webinar on Thursday, August 21, 2025 at 11 AM PDT / 2 PM EDT, featuring two leading oncologists: Dr. Seema Nagpal – neuro-oncologist Dr. Mohana Roy – thoracic oncologist Date & Time: Thursday, August 21,...

Plus Therapeutics (NASDAQ: PSTV) announced positive data from the ReSPECT-LM Phase 1 single dose escalation clinical trial, presented at the podium during the Society for Neuro-Oncology (SNO) / American Society of Clinical Oncology (ASCO) CNS Metastases Conference....

Plus Therapeutics (NASDAQ: PSTV) presented encouraging data from a retrospective analysis of the CNSide® Cerebrospinal Fluid (CSF) Assay Platform at the 2025 Society for Neuro-Oncology (SNO) / American Society of Clinical Oncology (ASCO) CNS Metastases Conference in...

Leptomeningeal Metastases (LM) is a devastating complication of advanced cancers, where cancer cells spread to the cerebrospinal fluid and leptomeninges of the brain and spinal cord. Research and collaboration are critical to improving outcomes for patients facing...

Mark your calendars!Date: Thursday, August 14, 2025Time: 6:15 PM ESTLocation: Baltimore Waterfront Marriott, Baltimore, MD We are proud to invite you to a compelling educational symposium at the 2025 SNO/ASCO CNS Metastases Conference, where leading voices in...

Today, on World Lung Cancer Day, we pause to recognize the strength of patients and survivors and to reflect on the critical need for continued research and innovation in lung cancer care. This annual observance shines a spotlight on the millions of people affected by...

Leptomeningeal metastases (LM) remain one of the most challenging complications in neuro-oncology. At Plus Therapeutics, we are committed to changing that. Our ongoing ReSPECT-LM dose-optimization trial is currently evaluating the optimal treatment regimen for...

Plus Therapeutics is pleased to announce the receipt of a $1.6 million advance payment from the Cancer Prevention and Research Institute of Texas (CPRIT), the world’s second-largest public cancer research funding agency. This payment is part of the $17.6 million grant...

Plus Therapeutics is pleased to announce its participation in the upcoming Society for Neuro-Oncology (SNO) / American Society of Clinical Oncology (ASCO) CNS Metastases Conference, taking place August 14–16, 2025, at the Baltimore Waterfront Marriott Hotel in...